YS BIOPHARMA TO MERGE WITH NASDAQ-LISTED SUMMIT HEALTHCARE ACQUISITION CORP.

Transaction values YS Biopharma at pre-money equity value of $834 million Certain investors ("Forward Purchase Investors") are expected to invest $30 million...

Related Keywords

Philippines ,United States ,Singapore ,Yi Zhang ,Shaanxi ,China ,Vietnam ,Republic Of ,United Arab Emirates ,Pakistan ,Cayman Islands ,Wilson Sonsini Goodrich Rosati ,Jingtian Gongcheng ,Hui Shao ,Calder Hong Kong ,Centers For Disease ,Company The Transaction ,Summit Healthcare Acquisition Sponsor ,Summit Healthcare Acquisition Corp ,Nasdaq ,Exchange Commission ,Yishengbio Co Ltd ,Background Paper Of World Health Organization ,Nasdaq Stock Market ,Ys Biopharma Co Ltd ,Forward Purchase Investors ,Summit Healthcare Acquisition ,Disease Control ,Background Paper ,World Health Organization ,Current Report ,Registration Statement ,Sonsini Goodrich ,Hong Kong ,Healthcare Acquisition ,